SCHEMBL41122

SCHEMBL41122

Oc1ccc(Cl)c(-c2ccc3nc(Nc4cccnc4)nn3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.53
PDGFRB P09619 2/20 0.53
LRRK2 Q5S007 3/20 0.49
PIK3CG P48736 4/20 0.46
PIK3CA P42336 2/20 0.46
JAK2 O60674 1/20 0.46
TTK P33981 4/20 0.41
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
CYP17A1 P05093 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41482 0.89 LRRK2 (0.46) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL41292 0.88 LRRK2 (0.49) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL41861 0.85 SRC (0.53) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL41398 0.84 LRRK2 (0.41) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL40873 0.83 LRRK2 (0.44) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL41009 0.83 LRRK2 (0.47) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL613388 0.83 LRRK2 (0.47) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL41177 0.82 LRRK2 (0.46) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL42778 0.82 LRRK2 (0.41) SRCPDGFRBLRRK2PIK3CGPIK3CA
SCHEMBL612688 0.82 LRRK2 (0.44) SRCPDGFRBLRRK2PIK3CGPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 US claimed
EP-2585439-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Fovea Pharmaceuticals (FR) 2013-05-01 EP claimed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 WO claimed
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 US disclosed
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 US disclosed
EP-2585439-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Fovea Pharmaceuticals (FR) 2013-05-01 EP disclosed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 WO disclosed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION CAMK2D, CAMK2A, CAMK2B SRC 401/4885PDGFRB 803/4885LRRK2 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.